“Clozapine & Valbenazine for Treatment of Tardive Cervical Dystonia: A Case Report”
Tardive Cervical Dystonia
DOI:
https://doi.org/10.46570/utjms.vol11-2023-526Keywords:
Dystonia, antipsychotics, schizophreniaAbstract
Cervical dystonia is a subtype of tardive dyskinesia characterized by smooth, sustained muscle contractions affecting the head, neck, and shoulders. This condition can be caused by antipsychotic medication exposure. It has a significant impact on the patient’s quality of life and represents a treatment challenge for providers. We present the case of a 26-year-old male with a history of schizophrenia treated with antipsychotic medications who presented with on and off smooth twisting movements of his neck and hand tremors. He was initially treated with benztropine and a decrease in the dose of his antipsychotic medications. However, when his symptoms continued to worsen, he was cross tapered to clozapine and valbenazine. Valbenazine is a VMAT2 inhibitor FDA approved for treatment of tardive dyskinesia, but there is little data regarding its use for tardive dystonia. The cervical dystonia impact profile-58 (CDIP-58) was administered to monitor the patient’s symptoms. Overall, there was a reduction in cervical dystonia symptoms within a 10-week period. This case illustrates the potential for clozapine plus valbenazine to treat tardive cervical dystonia.
References
References
Casey D (1990) Tardive dyskinesia. Western journal of medicine 153(5):535.
Burke RE; Fahn S; Jankovic J; Marsden C; Lang AE; Gollomp S, et al. (1982) Tardive dystonia: late?onset and persistent dystonia caused by antipsychotic drugs. Neurology 32(12):1335. DOI: https://doi.org/10.1212/WNL.32.12.1335
Molho ES; Feustel PJ; Factor SA (1998) Clinical comparison of tardive and idiopathic cervical dystonia. Movement disorders 13(3):486-9. DOI: https://doi.org/10.1002/mds.870130319
Godeiro-Junior C; Felício AC; de Carvalho Aguiar P; Borges V; Silva SM; Ferraz HB (2009) Neuroleptic-induced tardive cervical dystonia: clinical series of 20 patients. Canadian journal of neurological sciences 36(2):222-6. DOI: https://doi.org/10.1017/S0317167100006582
Skidmore F; Reich SG (2005) Tardive dystonia. Current treatment options in neurology 7(3):231-6. DOI: https://doi.org/10.1007/s11940-005-0016-0
van Harten PN; Kahn RS (1999)Tardive dystonia. Schizophrenia bulletin 25(4):741-8. DOI: https://doi.org/10.1093/oxfordjournals.schbul.a033415
Wojcik JD; Falk WE; Fink JS; Cole JO; Gelenberg AJ (1991) A review of 32 cases of tardive dystonia. The American journal of psychiatry 148(8), 1055–1059. DOI: https://doi.org/10.1176/ajp.148.8.1055
Yassa R; Nair V (1986) Dimitry R. Prevalence of tardive dystonia. Acta psychiatrica scandinavica 73(6):629-33. DOI: https://doi.org/10.1111/j.1600-0447.1986.tb02735.x
Duggal HS; Mendhekar DN (2008) Risperidone-induced tardive pharyngeal dystonia presenting with persistent dysphagia: a case report. Primary care companion to the Journal of clinical psychiatry 10(2):161. DOI: https://doi.org/10.4088/PCC.v10n0213b
Thenganatt MA; Jankovic J (2014) Treatment of dystonia. Neurotherapeutics 11(1):139-52. DOI: https://doi.org/10.1007/s13311-013-0231-4
Jinnah HA; Comella CL; Perlmutter J; Lungu C; Hallett M; Investigators DC (2018) Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy? Toxicon 147:89-95. DOI: https://doi.org/10.1016/j.toxicon.2017.09.004
Tarakad A. (2020) Clinical Rating Scales and Quantitative Assessments of Movement Disorders. Neurologic Clinics 38(2):231-54. DOI: https://doi.org/10.1016/j.ncl.2019.12.001
Loonen AJ; Ivanova SA (2020) Neurobiological mechanisms associated with antipsychotic drug-induced dystonia. Journal of Psychopharmacology 0269881120944156. DOI: https://doi.org/10.1177/0269881120944156
Greene P. Treatment of Tardive Dystonia. Therapy of Movement Disorders: Humana, Cham, 2019: 287-9. DOI: https://doi.org/10.1007/978-3-319-97897-0_65
Lako IM; van den Heuvel ER; Knegtering H; Bruggeman R; Taxis K (2013) Estimating Dopamine D2 Receptor Occupancy for Doses of 8 Antipsychotics: A Meta-Analysis. Journal of Clinical Psychopharmacology 33(5):675-81. DOI: https://doi.org/10.1097/JCP.0b013e3182983ffa
Touma KTB; Scarff JR (2018) Valbenazine and Deutetrabenazine for Tardive Dyskinesia. Innovations in clinical neuroscience 15(5-6):13-6.
Kilbourn MR; Koeppe RA (2019) Classics in Neuroimaging: Radioligands for the Vesicular Monoamine Transporter 2. ACS Chemical Neuroscience 10(1):25-9. DOI: https://doi.org/10.1021/acschemneuro.8b00429
Uhlyar S; Rey JA (2018) Valbenazine (Ingrezza): the first FDA-approved treatment for tardive dyskinesia. Pharmacy and Therapeutics 43(6):328.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Chandani Lewis, Christine Brennan
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
